Taysha Gene Therapies Proposes $200M Public Offering of Stock and Warrants
TSHA has more than doubled off its 52-week low of $2.25.
Summary
Taysha Gene Therapies announced a proposed $200 million underwritten public offering of common stock and pre-funded warrants, with an option for underwriters to purchase an additional 15%. This significant capital raise, representing about 10% of the company's market capitalization, will be dilutive to existing shareholders. While the company reported in its Q1 2026 filing that it had cash to fund operations into 2028, this offering provides substantial additional runway. The final terms and completion of the offering are subject to market conditions.
At the time of this announcement, TSHA was trading at $6.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.25 to $7.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.